HighTower Advisors
ASND icon

HighTower Advisors’s Ascendis Pharma A/S ASND Stock Holding History

HighTower Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,032
Closed -$2.81M – 3767
2025
Q1 		$2.81M Buy
18,032
+14,518
+413% +$2.07M ﹤0.01% 1342
2024
Q4 		$484K Buy
+3,514
New +$462K ﹤0.01% 2494
2024
Q3 		– Sell
-2,833
Closed -$393K – 3751
2024
Q2 		$393K Buy
+2,833
New +$385K ﹤0.01% 2501

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HighTower Advisors's ASND Position: Q2 2025 in Review

HighTower Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 18,032 shares — an estimated $2.81M sold.

HighTower Advisors first reported a position in ASND in Q2 2024 and held it in 3 quarters. The position peaked at $2.81M in Q1 2025. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

  • HighTower Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
  • HighTower Advisors sold 18,032 Ascendis Pharma A/S shares in Q2 2025, an estimated $2.81M.
  • HighTower Advisors first reported a position in Ascendis Pharma A/S in Q2 2024 and held it in 3 quarters.
  • HighTower Advisors's Ascendis Pharma A/S position peaked at $2.81M in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.